Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer

Journal of Clinical Oncology

Volumn 25, Issue 24, 2007, Pages 3759-3765

  Zuur, Charlotte L ^a   Simis, Yvonne J ^a   Lansdaal, Pauline E ^a   Hart, Augustinus A ^a   Schornagel, Jan H ^a   Dreschler, Wouter A ^a   Rasch, Coen R ^a   Balm, Alfons J ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; SODIUM THIOSULFATE;

ADULT; ADVANCED CANCER; ARTICLE; AUDITORY THRESHOLD; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EAR; FEMALE; HEAD AND NECK CANCER; HEALTH CARE ORGANIZATION; HEARING AID; HEARING LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OTOTOXICITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SPEECH PERCEPTION; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC AGENTS; AUDITORY THRESHOLD; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; EAR, INNER; FEMALE; HEAD AND NECK NEOPLASMS; HEARING LOSS; HEARING LOSS, SENSORINEURAL; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; MALE; RADIOTHERAPY DOSAGE; THIOSULFATES;

EID: 34548481762     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.9540     Document Type: Article

References (44)

1. Sankaranarayanan R, Masuyer E, Swaminathan R, et al: Head and neck cancer: A global perspective on epidemiology and prognosis. Anticancer Res 18:4779-4786, 1998
2. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet 355:949-955, 2000
3. Markman M, D'Acquisito R, Iannotti N, et al: Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulfate. J Cancer Res Clin Oncol 117:151-155, 1991
4. Myers SF, Blakley BW, Schwan S, et al: The "plateau effect" of cis-platinum-induced hearing loss. Otolaryngol Head Neck Surg 104:122-127, 1991
5. Laurell G, Jungnelius U: High-dose cisplatin treatment: Hearing loss and plasma concentrations. Laryngoscope 100:724-734, 1990
6. Anteunis LJC, Wanders SL, Hendriks JJT, et al: A prospective longitudinal study on radiation-induced hearing loss. Am J Surgery 168:408-411, 1994
7. Ho WK, Wei WI, Kwong DLW, et al: Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: A prospective study. Head Neck 21:547-553, 1999
8. Kwong DLW, Wei WI, Sham JST, et al: Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: A prospective study of the effect of radiation and cisplatin treatment. Int J Radiat Oncol Biol Phys 36:281-289, 1996
9. Raaijmakers E, Engelen AM: Is sensorineural hearing loss a possible side effect of nasopharyngeal and parotid irradiation? A systematic review of the literature. Radiother Oncol 65:1-7, 2002
10. Oh YT, Kim CH, Choi JH, et al: Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinoma. Radiother Oncol 72:79-82, 2004
11. Palazzi MP, Guzzo M, Tomatis S, et al: Improved outcome of nasopharyngeal carcinoma treated with conventional radiotherapy. Int J Radiat Oncol Biol Phys 60:1451-1458, 2004
12. Wang LF, Kuo WR, Ho KY, et al: A long-term study on hearing status in patients with nasopharyngeal carcinoma after radiotherapy. Otol Neurotol 25:168-173, 2004
13. Pan CC, Eisbruch A, Lee JS, et al: Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 61:1393-1402, 2005
14. Johannesen T, Rasmussen K, Winther FO, et al: Late radiation effects on hearing, vestibular function, and taste in brain tumor patients. Int J Radiat Oncol Biol Phys 53:86-90, 2002
15. Pearson SE, Meyer AC, Adams GL, et al: Decreased hearing after combined therapy for head and neck cancer. Am J Otolaryngol 27:76-80, 2006
16. Langenberg M, Terhaard CHJ, Hordijk GJ, et al: Simultaneous radio- and chemotherapy for squamous cell carcinoma of the head and neck in daily clinical practice: 5 years experience in a university hospital. Clin Otolaryngol Allied Sci 29:729-734, 2004
17. Cooper JS, Pajak TF, Forastiere AA, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-1944, 2004
18. Adelstein DJ, Li Y, Adams GL, et al: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003
19. Bernier J, Domenge C, Ozsahin M, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945-1952, 2004
20. Robbins KT, Storniolo AM, Kerber C, et al: Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol 12:2113-2120, 1994
21. Robbins KT, Vicario D, Seagren S, et al: A targeted supradose cisplatin chemoradiation protocol for advanced head and neck cancer. Am J Surg 168:419-422, 1994
22. Robbins KT, Kumar P, Wong FS, et al: Targeted chemoradiation for advanced head and neck cancer: Analysis of 213 patients. Head Neck 22:687-693, 2000
23. Balm AJM, Rasch CRN, Schornagel JH, et al: High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. Head Neck 26:485-493, 2004
24. Madasu R, Ruckenstein MJ, Leake F, et al: Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 123:978-981, 1997
25. Hiesiger EM, Green SB, Shapiro WR, et al: Results of a randomised trial comparing intra-arterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: Brain tumor cooperative group trial 8420A. J Neurooncol 25:143-154, 1995
26. Regine WF, Valentino J, John W, et al: High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy in patients with locally advanced primary squamous cell carcinoma of the head and neck: Report of a phase II study. Head Neck 22:543-549, 2000
27. Foote RL, Kasperbauer JL, Okuno SH, et al: A pilot study of high-dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0-N3M0 squamous cell carcinoma of the upper aerodigestive tract. Cancer 103:559-568, 2005
28. Madison MM, Sorenson JM, Samant S, et al: The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation. J Neurooncol 72:67-75, 2005
29. Kovács AF, Schiemann M, Turowski B: Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docetaxel: Three year results of a pilot study. J Craniomaxillofac Surg 30:112-120, 2002
30. Madajewicz S, Chowhan N, Tfayli A, et al: Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy. Cancer 88:2350-2356, 2000
31. Rasch CRN, Balm AJM, Schornagel JH, et al: Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer, early results of a multi-institutional trial. Presented at the 48th Annual Meeting of ASTRO, Philadelphia, PA, November 5-9, 2006 (abstr)
32. National Cancer Institute: Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0. http://ctep.cancer.gov/ reporting/ctc.html
33. Hoebers FJ, Pluim D, Verheij M, et al: Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT). Int J Cancer 119:750-756, 2006
34. Rademaker-Lakhai JM, Crul M, Zuur L, et al: Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol 24:918-924, 2006
35. Sileni VC, Fosser V, Maggian P, et al: Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cell cancer. Cancer Chemother Pharmacol 30:221-225, 1992
36. Dickey DT, Muldoon LL, Kraemer DF, et al: Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hear Res 193:25-30, 2004
37. Dickey DT, Wu YJ, Muldoon LL, et al: Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 314:1052-1058, 2005
38. Wang J, Faulconbridge RVL, Fetoni A, et al: Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. Neuropharmacology 45:380-393, 2003
39. Dropcho EJ, Rosenfeld SS, Morawetz RB, et al: Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. J Clin Oncol 10:452-458, 1992
40. Bohne BA, Marks JE, Glasgow GP, et al: Delayed effects of ionising radiation on the ear. Laryngoscope 95:818-828, 1985
41. Greene JS, Giddings NA, Jacobson JT: Effect of irradiation on guinea pig ABR thresholds. Otolaryngol Head Neck Surg 107:763-768, 1992
42. Lau SK, Wei WI, Sham JST, et al: Early changes of auditory brain stem evoked response after radiotherapy for nasopharyngeal carcinoma: A prospective study. J Laryngol Otol 106:887-892, 1992
43. Leighton SEJ, Kay R, Leung SF, et al: Auditory brainstem responses after radiotherapy for nasopharyngeal carcinoma. Clin Otolaryngol 22:350-354, 1997
44. Low WK, Burgess BS, Fong KW, et al: Effect of radiotherapy on retro-cochlear auditory pathways. Laryngoscope 115:1823-1826, 2005